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of incident ET. Antihypertensive medication use was not as-
sociated with prevalent or incident PD. Calcium channel 
blocker use was marginally reduced in prevalent dementia 
cases (OR adjusted = 0.63, p = 0.06) but was not associated with 
reduced risk of incident dementia (RR adjusted = 1.02, p = 0.95). 
 Conclusions: We did not find evidence of a protective effect 
of antihypertensive medications in these three neurode-
generative disorders.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 The identification of modifiable risk factors for neu-
rodegenerative diseases has important implications in 
terms of slowing or halting the progression of those dis-
eases. Recent interest in antihypertensive agents, espe-
cially calcium channel blockers, has been sparked by the 
notion that these medications, which inhibit oxidative 
stress and the inflammatory response, might be neuro-
protective  [1, 2] . A modest literature, with mixed results, 
has examined whether the use of these medications might 
lower the odds or risk of Parkinson’s disease (PD) or
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 Abstract 
 Background: Recent interest in antihypertensive agents, es-
pecially calcium channel blockers, has been sparked by the 
notion that these medications may be neuroprotective. A 
modest literature, with mixed results, has examined whether 
these medications might lower the odds or risk of Par-
kinson’s disease (PD) or dementia. There are no data for es-
sential tremor (ET).  Objective: To examine the association 
 between antihypertensive use (defined broadly and by indi-
vidual subclasses) and ET, PD and dementia. For each disor-
der, we used cross-sectional data (association with prevalent 
disease) and prospective data (association with incident dis-
ease).  Methods: Prospective population-based study in 
Spain enrolling 5,278 participants at baseline.  Results: Use 
of antihypertensive medications (aside from  ! -blockers) was 
similar in prevalent ET cases and controls. Baseline use of an-
tihypertensive agents was not associated with reduced risk 
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Alzheimer’s disease (AD)  [3–5] . With one exception  [6] , 
these studies all have been cross-sectional  [3–5] . Essential 
tremor (ET), associated with mixed degenerative pathol-
ogies (cerebellar degeneration in most cases and Lewy 
bodies in others)  [7] , is one of the more common neuro-
degenerative disorders  [8] , yet the protective role of anti-
hypertensive agents has not been studied in this disease. 
The current study used a population-based design to ex-
amine the association between antihypertensive use (de-
fined broadly as well as by individual subclasses) in each 
of these three late-life degenerative disorders (PD, de-
mentia, and ET). For each disorder, the study used cross-
sectional data to examine the association with prevalent 
disease as well as prospective data to examine the asso-
ciation with risk of incident disease.
 Methods 
 Study Population 
 The Neurological Disorders in Central Spain (NEDICES) is a 
population-based survey of the frequency and determinants of 
major age-associated conditions of the elderly. The study popula-
tion comprised subjects  6 65 years of age taken from the census 
of 3 communities in central Spain: Las Margaritas (a working-
class neighborhood in greater Madrid), Lista (a professional 
neighborhood in central Madrid), and Arévalo (an agricultural 
zone northwest of Madrid)  [9] . We have reported elsewhere a de-
tailed account of the background, study population, and methods 
of the survey  [9–11] . Written (signed) informed consent was ob-
tained from all subjects at the time of enrollment.
 Study Evaluation 
 Evaluations were performed at baseline (1994–1995) and at 
follow-up (1997–1998). As detailed previously  [9–13] , the evalua-
tions included a demographic and medical questionnaire that 
screened for neurological disorders (ET, dementia, PD, stroke). 
Persons who screened positive for neurological disorders under-
went a neurologic evaluation that included a standardized medi-
cal history (including current medications), a general neurologic 
examination, and the motor portion of the Unified Parkinson’s 
Disease Rating Scale (UPDRS)  [14] , which were performed by se-
nior neurologists. Participants underwent a short neuropsycho-
logical test battery. This battery, which was implemented by 
trained lay interviewers, has been described in previous studies 
 [12, 15] .
 Diagnoses 
 Participants were diagnosed as having ET if they had an action 
tremor of the head or limbs without any other recognizable cause 
 [9, 16] . The tremor had to be of gradual onset (i.e., slow and pro-
gressive) and either (1) present for at least 1 year or (2) accompa-
nied by a family history of the same disorder (one or more report-
edly affected first-degree relatives)  [9, 16] . On an Archimedes spi-
ral, tremor severity had to be moderate or greater (rating  6 2 on 
the handwriting scale of Bain and Findley [17] ). Based on their 
medical history, participants were not considered to have ET if 
their tremor was related to alcohol withdrawal, hyperthyroidism, 
anxiety, or medications. Similarly, based on their neurologic ex-
amination, participants with action tremor attributed to PD, dys-
tonia, orthostatic tremor, or other movement disorders were not 
considered to have ET. Participants initially identified as ET were 
subsequently independently evaluated by 2 additional neurolo-
gists who examined the participant together. Participants were 
classified as having ET only when the 3 neurologists agreed. If ET 
was diagnosed, data on age of onset were elicited.
 The diagnosis of dementia was made by consensus of 2 neu-
rologists based on medical, neurological and, if available, neuro-
psychological information  [15] . The medical records of all par-
ticipants who received a diagnosis of dementia were also review-
ed by a senior neurologist (F.B.P.) with the aid of a psychologist 
(F.S.-S.; see Acknowledgments). If there were doubts about any 
aspect of the dementia diagnosis, additional information (mainly 
from family doctors) was elicited. For the diagnosis of dementia, 
we applied the Diagnostic and Statistical Manual of Mental Dis-
orders (DSM)-IV criteria  [18] and required evidence of cognitive 
deficit (neuropsychological test battery, clinical mental status ex-
amination) as well as evidence of impairment in social or occupa-
tional function. If dementia was diagnosed, data on age at onset 
were elicited.
 Parkinsonism was diagnosed when at least 2 cardinal signs 
(resting tremor, rigidity, bradykinesia, and impaired gait/postur-
al reflexes) were present  [19, 20] . PD was diagnosed in patients 
without secondary causes or atypical features. A second neurolo-
gist reexamined all diagnosed PD patients. All diagnoses were 
then discussed and adjudicated by a panel composed of 3 senior 
neurologists. If PD was diagnosed, data on age at onset were elic-
ited.
 Data Analyses 
 Statistical analyses were performed by E.D.L. using SPSS ver-
sion 16.0 (SPSS, Inc., Chicago, Ill., USA). Baseline characteristics 
of participants ( table 1 ) were compared using Student’s t tests and 
 " 2 tests. Antihypertensive agents were first treated as a single class 
of medication and then divided into subclasses: angiotensin-con-
verting enzyme (ACE) inhibitors,  ! -blockers, calcium channel 
blockers, diuretics, nitrates and vasodilators ( table 2 ). We also 
distinguished between ‘any antihypertensive agent’ and ‘any an-
tihypertensive agent excluding  ! -blockers’ because of the propen-
sity of ET cases to be treated with  ! -blockers  [21] . In cross-sec-
tional analyses ( table 3 ), logistic regression models were used to 
examine the relationship between antihypertensive agent use (yes 
vs. no, independent variable) and diagnosis (ET, PD, dementia, in 
different models), yielding odds ratios (ORs) with 95% confidence 
intervals (CIs). We adjusted for variables that were associated with 
diagnosis in univariate analyses. Given the emphasis on calcium 
channel blockers in previous literature  [3, 5] , we highlighted this 
subclass of antihypertensives in these analyses. Attributable risk 
was calculated by subtracting the risk of the non-exposed group 
from the risk for the exposed group (e.g., the proportion of anti-
hypertensive medication users with ET – the proportion of non-
users with ET). In prospective analyses, we used Cox proportion-
al hazards models to estimate the relative risk of incident disease 
(ET, PD, or dementia, in different models); this generated relative 
risks (RRs) with 95% CIs ( table 4 ). Person-years for participants 
who developed incident disease were calculated as the time be-
tween the baseline evaluation and the reported date of disease 
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onset. When the date of onset of disease was unknown, person-
years were calculated as the midpoint between the first evaluation 
and the follow-up evaluation. We began with an unadjusted mod-
el and then, in adjusted models, included as confounders those 
variables that were associated with disease in univariate analyses. 
Due to the emphasis on calcium channel blockers in previous lit-
erature  [3, 5] , we highlighted this subclass of antihypertensives in 
these analyses.
 Results 
 Cross-Sectional Analyses 
 There were 5,278 participants at baseline. The baseline 
characteristics of participants with prevalent ET, preva-
lent PD, and prevalent dementia were compared to those 
of participants with none of these disorders (controls); 
Table 1. Baseline characteristics of 5,278 participants
Baseline characteristics Essential tremor Parkinson’s disease Dementia Controls
Participants 256 81 306 4,663
Age, years (mean 8 SD) 75.587.1c 77.085.6c 82.687.2c 73.786.6
Female gender 149 (58.2%) 38 (46.9%) 209 (68.3%)c 2,662 (57.1%)
Educational level
Illiterate








































Diabetes mellitus1 44 (17.4%) 14 (17.7%) 44 (16.4%) 744 (16.0%)
Heart disease1 26 (10.2%) 2 (2.6%)a 32 (11.8%) 451 (9.7%)
Self-reported depression1 97 (41.5%)c 35 (45.5%)c 82 (33.3%)b 954 (20.5%)
Some participants had more than one neurological disease: there were 3 with essential tremor and Parkin-
son’s disease, 12 with essential tremor and dementia, and 13 with Parkinson’s disease and dementia. Unless 
otherwise indicated the values are the number of participants with percentages in parentheses.
a p < 0.05 compared to controls; b p < 0.01 compared to controls; c p < 0.001 compared to controls.
1 In some cells, data are missing and percentage reflects total available data.
Table 2. Use of antihypertensive agents in essential tremor, Parkinson’s disease, dementia and controls
Antihypertensive agent Essential tremor Parkinson’s disease Dementia Controls
Any antihypertensive agent 129 (50.4%)a 41 (50.6%) 131 (42.8%) 2,063 (44.2%)
Any antihypertensive agent (excluding !-blockers) 122 (47.7%) 38 (46.9%) 130 (42.5%) 1,998 (42.8%)
ACE-inhibitors 31 (12.1%) 10 (12.3%) 33 (10.8%) 592 (12.7%)
!-Blockers 17 (6.6%)b 3 (3.7%) 6 (2.0%)a 187 (4.0%)
Calcium channel blockers 27 (10.5%) 11 (13.6%) 23 (7.5%)a 514 (11.0%)
Diuretics 54 (21.1%) 16 (19.8%) 65 (21.2%) 861 (18.5%)
Nitrates 10 (3.9%) 3 (3.7%) 25 (8.2%)b 231 (5.0%)
Vasodilators 41 (16.0%)d 8 (9.9%) 39 (12.7%) 461 (9.9%)
Some participants were taking more than one antihypertensive agent. Values are given as the number of participants with percent-
ages in parentheses.
a p < 0.10 compared to controls; b p < 0.05 compared to controls; c p < 0.01 compared to controls; d p < 0.001 compared to controls.
 Antihypertensives and Risk of 
Neurological Disease 
Neuroepidemiology 2009;33:286–292 289
differences in age, gender, educational level, and self-re-
ported depression were apparent ( table 1 ).
 Participants who used an antihypertensive agent (n = 
2,352 [44.6%]) were older than those who did not (mean 
 8 SD = 74.9  8 6.9 vs. 73.9  8 7.0 years; p  ! 0.001). A 
larger proportion of women than men used an antihyper-
tensive agent (1,524/3,040 [50.1%] women vs. 828/2,238 
[37.0%] men; p  ! 0.001). Use of an antihypertensive agent 
was highest in Lista and lowest in Las Margaritas (p  ! 
0.001) but did not differ by educational level (p = 0.84). A 
larger proportion of participants with diabetes mellitus 
(p  ! 0.001), heart disease (p  ! 0.001), and self-reported 
depression (p = 0.002) used an antihypertensive agent 
when compared to their counterparts without each con-
dition.
 A marginally larger proportion of ET cases than con-
trols were on an antihypertensive agent (50.4 vs. 44.2%; 
 table 2 ); however, this difference was largely due to the 
higher proportion of ET cases taking  ! -blockers (pre-
sumably for tremor). When  ! -blockers were excluded, 
use of an antihypertensive medication did not differ be-
tween ET cases and controls ( table 2 ). A larger proportion 
of ET cases were taking vasodilators, but ET cases and 
controls did not differ with regard to each of the other 
subclasses of antihypertensives. PD cases and controls 
did not differ with regard to antihypertensive medication 
use. A marginally lower proportion of demented cases 
were taking  ! -blockers and calcium channel blockers; a 
higher proportion was taking nitrates ( table 2 ).
 In logistic regression models, use of antihypertensive 
agents was not associated with odds of ET or PD after ad-
Table 3. Cross-sectional analyses (odds of prevalent disease with antihypertensive medication use)
Antihypertensive agent Essential tremor Parkinson’s disease Dementia




















In logistic regression models, use of an antihypertensive agent 
was the independent variable, and diagnosis (essential tremor, 
Parkinson’s disease, dementia, in different models) was the de-
pendent variable. Unadjusted models are reported (upper row in 
each cell) and then models that adjusted for age, gender, education 
and self-reported depression (lower row in each cell). Results are 
given as OR (95% CI) and p values. For any antihypertensive 
agent, the attributable risk was: –1.1% (essential tremor); 0.4% 
(Parkinson’s disease), and –0.4% (dementia).
Table 4. Prospective analyses (risk of incident disease with antihypertensive medication use)
Antihypertensive agent Essential tremor Parkinson’s disease Dementia




















In Cox proportional hazards models, diagnosis (essential 
tremor vs. control, Parkinson’s disease vs. control, dementia vs. 
control, in different models) was the outcome variable and use of 
an antihypertensive agent was the predictor variable. Unadjusted 
models are reported (upper row in each cell) and then models that 
adjusted for age, gender, education, and depressive symptoms 
(lower row in each cell). Results are given as the risk ratio (95% 
CI) and p values.
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justing for age, gender, education and depressive symp-
toms ( table 3 ). In similar adjusted analyses, only use of 
calcium channel blockers was marginally lower in de-
mented cases ( table 3 ).
 Prospective Analyses 
 We excluded participants with prevalent ET, PD or de-
mentia at baseline and those for whom follow-up data 
were unavailable. Of the 3,942 remaining participants, 
there were 83 incident ET cases, 30 incident PD cases and 
161 participants with incident dementia. In unadjusted 
and adjusted Cox models, baseline use of antihyperten-
sive agents was not associated with reduced risk of inci-
dent ET; in fact, it was marginally associated with in-
creased risk of incident ET ( table 4 ). Baseline use of these 
medications was not associated with reduced risk of inci-
dent PD or incident dementia in Cox models ( table 4 ).
 Discussion 
 Several recent studies have related calcium channel 
blockers and ACE inhibitors to possible neuroprotective 
effects  [1–3] . Calcium channel blockers, for example, have 
been shown to reduce degeneration of dopaminergic 
neurons in mesencephalic neuron-glia cultures in a dose-
dependent manner  [2] .
 In the current study, a marginally larger proportion of 
prevalent ET cases than controls were on an antihyper-
tensive agent; however, this difference was largely due to 
the higher proportion of ET cases taking  ! -blockers (pre-
sumably for tremor). Use of other antihypertensive med-
ications (including calcium channel blockers) was similar 
in ET cases and controls. Baseline use of antihypertensive 
agents was not associated with reduced risk of incident 
ET; in fact, it was marginally associated with increased 
risk of incident ET. Antihypertensive medication use was 
not associated with either prevalent or incident PD. Cal-
cium channel blocker use was marginally reduced in 
prevalent dementia cases but was not associated with in-
creased/reduced risk of incident dementia. Hence, there 
is no evidence from this study that antihypertensives re-
duced the risk of any of these disorders.
 One case-control study demonstrated a reduction in 
the odds of PD with use (in general) of antihypertensive 
medications  [4] . That study was a case-control study nest-
ed within a prospective cohort study of 13,979 residents 
of Leisure World Laguna Hills, California. They identi-
fied 395 PD cases and each was matched to 6 controls. 
The odds of PD was significantly reduced in users of 
blood pressure medication (adjusted OR 0.62, 95% CI 
0.48–0.80). One other study showed a reduced odds of 
prevalent PD with calcium channel blocker use but not 
with other antihypertensive drugs  [3] . That was a case-
control analysis within the UK-based General Practice 
Research Database. They identified 3,637 PD cases and 
an equal number of matched controls. As compared to 
nonuse of antihypertensive drugs, the adjusted OR for 
current use of calcium channel blockers was 0.77 (95% CI 
0.63–0.95). A 3rd study showed no change in odds  [5] . We 
also found no association. Hence, cross-sectional studies 
have reported mixed results. Whether demographic or 
other population-specific factors could account for these 
mixed results is an interesting question but one that is 
difficult to address. Ethnicity is not reported in most of 
these studies but presumably was predominantly Cauca-
sian. The four studies have been conducted in a variety of 
settings in different countries (UK, Australia, USA, 
Spain), which could account for some variance in results. 
Importantly, no prior studies of PD have used prospec-
tive, longitudinal data. In the current study, antihyper-
tensive medication use (in general as well as with regard 
to specific classes) was not associated with either preva-
lent PD or a reduction in the risk of incident PD.
 There is one caveat with respect to PD and parkinson-
ism. Although we have been discussing the possible neu-
roprotective effects of calcium channel blockers, curious-
ly there is also literature on the development of drug-in-
duced parkinsonism in the setting of current calcium 
channel blocker use  [22] . The pathological mechanism 
responsible for this is still not completely understood; 
however, the occurrence of drug-induced parkinsonism 
in this setting would make it more difficult for epidemio-
logical studies to detect a neuroprotective effect of these 
agents (i.e., lower risk of PD) should such an effect exist.
 In terms of dementia, the literature is more limited. 
One study, which was a prospective longitudinal study, 
did not find that the use of calcium channel blockers was 
associated with a reduced risk of developing incident AD 
 [6] . Our results, which look more broadly at dementia, are 
in concordance with the earlier study. Interestingly, there 
is a sizable literature about the relationship among hyper-
tension, antihypertensive drug use and dementia. Studies 
have shown that cerebrovascular risk factors (hyperten-
sion included) are related to the development of dementia 
and AD  [23, 24] . In NEDICES, hypertensive participants 
had a greater risk of developing dementia, and the com-
bination of several cardiovascular risk factors has been 
related to the incidence of dementia and AD  [25] . A Co-
chrane review of several blood pressure-lowering trials 
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did not demonstrate that antihypertensive medications 
decreased dementia incidence  [26] , but a more recent tri-
al indicates a possible effect  [27] .
 There have been no prior studies, either cross-section-
al or longitudinal, of antihypertensive medication use 
and reduced odds or risk of ET. Our study does not sup-
port such an association.
 One limitation is that we did not take into account the 
dose of these medications, so we were not able to evaluate 
whether higher current dose or cumulative dose of these 
medications was associated with lower risk of these dis-
orders. One other issue is that orthostatic hypotension 
may be a feature of PD or PD medications. The presence 
of hypotension could have resulted in the discontinua-
tion of antihypertensive medications in some PD cases, a 
scenario that we were not able to assess. However, this 
would only have been a concern in our cross-sectional 
analyses; in the prospective analyses, we assessed antihy-
pertensive medication use prior to the onset of PD or PD 
medication use. Strengths of the study include: its popu-
lation-based design; division of antihypertensive medica-
tions into separate subclasses; the ability to supplement 
our initial cross-sectional analyses with prospective anal-
yses that examined baseline exposure to medication and 
risk of incident disease, and the broad examination of 3 
neurodegenerative disorders.
 In summary, we did not find evidence to support a 
protective effect of antihypertensive medications (in-
cluding calcium channel blockers) in these 3 neurode-
generative disorders.
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